| First Author | Broder C | Year | 2013 |
| Journal | Biochem J | Volume | 450 |
| Issue | 2 | Pages | 253-64 |
| PubMed ID | 23410038 | Mgi Jnum | J:198164 |
| Mgi Id | MGI:5495608 | Doi | 10.1042/BJ20121751 |
| Citation | Broder C, et al. (2013) The metalloproteases meprin alpha and meprin beta: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. Biochem J 450(2):253-64 |
| abstractText | The metalloproteases meprin alpha and meprin beta exhibit structural and functional features that are unique among all extracellular proteases. Although meprins were discovered more than 30 years ago, their precise substrates and physiological roles have been elusive. Both enzymes were originally found to be highly expressed in kidney and intestine, which focused research on these particular tissues and associated pathologies. Only recently it has become evident that meprins exhibit a much broader expression pattern, implicating functions in angiogenesis, cancer, inflammation, fibrosis and neurodegenerative diseases. Different animal models, as well as proteomics approaches for the identification of protease substrates, have helped to reveal more precise molecular signalling events mediated by meprin activity, such as activation and release of pro-inflammatory cytokines. APP (amyloid precursor protein) is cleaved by meprin beta in vivo, reminiscent of the beta-secretase BACE1 (beta-site APP-cleaving enzyme 1). The subsequent release of Abeta (amyloid beta) peptides is thought to be the major cause of the neurodegenerative Alzheimer's disease. On the other hand, ADAM10 (a disintegrin and metalloprotease domain 10), which is the constitutive alpha-secretase, was shown to be activated by meprin beta, which is itself shed from the cell surface by ADAM10. In skin, both meprins are overexpressed in fibrotic tumours, characterized by massive accumulation of fibrillar collagens. Indeed, procollagen III is processed to its mature form by meprin alpha and meprin beta, an essential step in collagen fibril assembly. The recently solved crystal structure of meprin beta and the unique cleavage specificity of these proteases identified by proteomics will help to generate specific inhibitors that could be used as therapeutics to target meprins under certain pathological conditions. |
